Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label Dose-finding and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL)

Next Previous
Trial Profile

Open-label Dose-finding and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etivelcabtagene erigedleucel (Primary) ; Alemtuzumab; Cyclophosphamide; Fludarabine
  • Indications B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Acronyms NatHaLi-01
  • Sponsors Cellectis

Most Recent Events

  • 08 Jan 2026 According to a Cellectis media release, patient enrollment will begin in the cohort with low dose interleukin-2 (IL-2) support, in Q1 2026. Results from the full Phase 1 dataset, including results from the IL-2 combination, are expected in Q4 2026.
  • 08 Dec 2025 According to a Cellectis media release, the full Phase 1 dataset expected in 2026.
  • 08 Dec 2025 According to a Cellectis media release,updated data of patients from this trial presented at the 67th Annual Meeting of the American Society of Hematology (ASH) in Orlando, FL.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top